[1]
|
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D. et al. (2009). Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums, 14, 197-206.
|
[2]
|
Berman, R. M., Thase, M. E., Trivedi, M. H., Hazel, J. A., Marler, S. V., McQuade, R. D. et al. (2011). Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatric Disease and Treatment, 7, 303-312. http://dx.doi.org/10.2147/NDT.S18333
|
[3]
|
Blair, J. R., & Spreen, O. (1989). Predicting premorbid IQ: A revision of the national adult reading test. The Clinical Neuropsychologist, 3, 129-136. http://dx.doi.org/10.1080/13854048908403285
|
[4]
|
Burdick, K. E., Braga, R. J., Nnadi, C. U., Shaya, Y., Stearns, W. H., & Malhotra, A. K. (2012). Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: Targeting cognitive dysfunction. Journal of Clinical Psychiatry, 73, 103-112.
http://dx.doi.org/10.4088/JCP.11m07299
|
[5]
|
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T. et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. The Journal of Pharmacology and Experimental Therapeutics, 302, 381-389.
http://dx.doi.org/10.1124/jpet.102.033175
|
[6]
|
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C. et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96. http://dx.doi.org/10.1016/0893-133X(94)00129-N
|
[7]
|
Cambridge Cognition Limited (2004). CANTABeclipse test administration guide.
|
[8]
|
Cuijpers, P., Beekman, A. T., & Reynolds 3rd, C.F. (2012). Preventing depression: A global priority. The Journal of the American Medical Association, 307, 1033-1034.
http://dx.doi.org/10.1001/jama.2012.271
|
[9]
|
Davidson, J. R. (2010). Major depressive disorder treatment guidelines in America and Europe. The Journal of Clinical Psychiatry, 71, e04.
http://dx.doi.org/10.4088/JCP.9058se1c.04gry
|
[10]
|
Endicott, J., & Nee, J. (1993). Quality of life experience & satisfaction questionnaire: A new scale. Psychopharmacology Bulletin, 29, 321-326.
|
[11]
|
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2010). Defining and measuring functional recovery from depression. CNS Drugs, 24, 267-284.
http://dx.doi.org/10.2165/11530230-000000000-00000
|
[12]
|
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56-62.
http://dx.doi.org/10.1136/jnnp.23.1.56
|
[13]
|
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K. et al. (2010). Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. The American Journal of Psychiatry, 167, 748-751.
http://dx.doi.org/10.1176/appi.ajp.2010.09091379
|
[14]
|
Jaeger, J., Berns, S., Uzelac, S., & Davis-Conway, S. (2006). Neurocognitive deficits and disability in major depressive disorder. Psychiatry Research, 145, 39-48.
http://dx.doi.org/10.1016/j.psychres.2005.11.011
|
[15]
|
Kalsekar, I., Wagner, J. S., DiBonaventura, M., Bates, J., Forbes, R., & Hebden, T. (2012). Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: Results from the National Health and Wellness Survey. Health and Quality of Life Outcomes, 10, 81.
http://dx.doi.org/10.1186/1477-7525-10-81
|
[16]
|
Keller, M. B. (2003). Past, present, and future directions for defining optimal treatment outcome in depression: Remission and beyond. The Journal of the American Medical Association, 289, 3152-3160.
http://dx.doi.org/10.1001/jama.289.23.3152
|
[17]
|
Kurian, B. T., Greer, T. L., & Trivedi, M. H. (2009). Strategies to enhance the therapeutic efficacy of antidepressants: Targeting residual symptoms. Expert Review of Neurotherapeutics, 9, 975-984.
http://dx.doi.org/10.1586/ern.09.53
|
[18]
|
Landro, N. I., Stiles, T. C., & Sletvold, H. (2001). Neuropsychological function in nonpsychotic unipolar major depression. Neuropsychiatry, Neuropsychology, & Behavioral Neurology, 14, 233-240.
|
[19]
|
Levkovitz, Y., Alpert, J. E., Brintz, C. E., Mischoulon, D., & Papakostas, G. I. (2012). Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Journal of Affective Disorders, 136, 1174-1178. http://dx.doi.org/10.1016/j.jad.2011.04.059
|
[20]
|
Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine, 3, e442.
http://dx.doi.org/10.1371/journal.pmed.0030442
|
[21]
|
McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H. et al. (2011). Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. Journal of Clinical Psychopharmacology, 31, 180-186. http://dx.doi.org/10.1097/JCP.0b013e31820ebd2c
|
[22]
|
McDermott, C. L., & Gray, S. L. (2012). Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. The Annals of Pharmacotherapy, 46, 599-605. http://dx.doi.org/10.1345/aph.1Q445
|
[23]
|
McIntyre, R. S., Fallu, A., & Konarski, J. Z. (2006). Measurable outcomes in psychiatric disorders: Remission as a marker of wellness. Clinical Therapeutics, 28, 1882-1891.
http://dx.doi.org/10.1016/j.clinthera.2006.11.007
|
[24]
|
Mundt, J. C., Marks, I. M., Shear, M. K., & Griest, J. H. (2002). The work and social adjustment scale: A simple measure of impairment in functioning. The British Journal of Psychiatry, 180, 461-464.
http://dx.doi.org/10.1192/bjp.180.5.461
|
[25]
|
Nelson, J. C., Pikalov, A., & Berman, R. M. (2008). Augmentation treatment in major depressive disorder: Focus on aripiprazole. Neuropsychiatric Disease and Treatment, 4, 937-948.
|
[26]
|
Nelson, J. C., Thase, M. E., Bellocchio, E. E., Rollin, L. M., Eudicone, J. M., McQuade, R. D. et al. (2012). Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. International Clinical Psychopharmacology, 27, 125-133.
http://dx.doi.org/10.1097/YIC.0b013e3283502791
|
[27]
|
Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R. et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report. Psychological Medicine, 40, 41-50.
http://dx.doi.org/10.1017/S0033291709006011
|
[28]
|
Reimherr, F. W., Martin, M. L., Eudicone, J. M., Marchant, B. K., Tran, Q. V., Pikalov, A. et al. (2010). A pooled MADRS/IDS cross-correlation analysis: Clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. Journal of Clinical Psychopharmacology, 30, 300-305.
http://dx.doi.org/10.1097/JCP.0b013e3181db320f
|
[29]
|
Reynolds 3rd, C. F., Butters, M. A., Lopez, O., Pollock, B. G., Dew, M. A., Mulsant, B. H. et al. (2011). Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Archives of General Psychiatry, 68, 51-60. http://dx.doi.org/10.1001/archgenpsychiatry.2010.184
|
[30]
|
Rush, A. J., Giles, D. E., Schlesser, M. A., Fulton, C. I., Weissenburger, J., & Burns, C. (1986). The inventory for depressive symptomatology (IDS): Preliminary findings. Psychiatry Research, 18, 65-87.
http://dx.doi.org/10.1016/0165-1781(86)90060-0
|
[31]
|
Sanislow, C. A., Pine, D. S., Quinn, K. J., Kozak, M. J., Garvey, M. A., Heinssen, R. K. et al. (2010). Developing constructs for psychopathology research: Research domain criteria. Journal of Abnormal Psychology, 119, 631-639. http://dx.doi.org/10.1037/a0020909
|
[32]
|
Seeger, T. F., Seymour, P. A., Schmidt, A. W., Zorn, S. H., Schulz, D. W., Lebel, L. A. et al. (1995). Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. The Journal of Pharmacology and Experimental Therapeutics, 275, 101-113.
|
[33]
|
Tadori, Y., Forbes, R. A., McQuade, R. D., & Kikuchi, T. (2008). Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. European Journal of Pharmacology, 597, 27-33.
http://dx.doi.org/10.1016/j.ejphar.2008.09.008
|
[34]
|
Thase, M. E., Trivedi, M. H., Nelson, J. C., Fava, M., Swanink, R., Tran, Q. V. et al. (2008). Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies. Primary Care Companion to the Journal of Clinical Psychiatry, 10, 440-447. http://dx.doi.org/10.4088/PCC.v10n0603
|
[35]
|
Veiel, H. O. (1997). A preliminary profile of neuropsychological deficits associated with major depression. Journal of Clinical and Experimental Neuropsychology, 19, 587-603.
http://dx.doi.org/10.1080/01688639708403745
|
[36]
|
Ware, J. E., & Snow, K. K. (1993). SF-36 health survey manual and information guide. Boston, MA: Health Institute, New England Medical Center.
|
[37]
|
Zimmerman, M., Martinez, J., Attiullah, N., Friedman, M., Toba, C., & Boerescu, D. A. (2012). How should residual symptoms be defined in depressed patients who have remitted? Comprehensive Psychiatry, 54, 91-96. http://dx.doi.org/10.1016/j.comppsych.2012.06.010
|